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ABSTRACT
Cytochrome P450 1B1 (CYP1B1) is recognized as a universal tumor biomarker 
and a feasible therapeutic target due to its specific overexpression in cancer 
tissues. Despite its up-regulation in prostate cancer (PCa), biological significance 
and clinicopathological features of CYP1B1 are still elusive. Here, we show that 
overexpression or hyperactivation of CYP1B1 stimulated proliferative, migratory 
and invasive potential of non-tumorigenic PCa cells. Attenuation of CYP1B1 with its 
specific small hairpin (sh) RNAs greatly reduced proliferation through apoptotic cell 
death and impaired migration and invasion in PCa cells. Intratumoral injection of 
CYP1B1 shRNA attenuated growth of pre-existing tumors. The antitumor effect of 
CYP1B1 shRNA was also observed in prostate tumor xenograft mouse models. Among 
the genes altered by CYP1B1 knockdown, reduction of caspase-1 (CASP1) activity 
attenuated the antitumor effect of CYP1B1 inhibition. Indeed, CYP1B1 regulates CASP1 
expression or activity. Finally, CYP1B1 expression was increased in higher grades 
of PCa and overall survival was significantly reduced in patients with high levels of 
CYP1B1 protein. CYP1B1 expression was reversely associated with CASP1 expression 
in clinical tissue samples. Together, our results demonstrate that CYP1B1 regulates 
PCa tumorigenesis by inhibiting CASP1 activation. Thus, the CYP1B1-CASP1 axis may 
be useful as a potential biomarker and a therapeutic target for PCa.
INTRODUCTION
The cytochrome P450 (CYP) superfamily is 
involved in the metabolism of a diverse range of 
xenobiotics and endogenous compounds. Among 
CYP1 family members, CYP1B1 is the only member 
of the CYP1B subfamily and mainly implicated in the 
hydroxylation of estrogen and activation of environmental 
carcinogens [1]. CYP1B1 protein is found in the cancer 
cells of various cancerous tissues but is undetectable or 
minimally expressed in the adjacent normal cells of cancer 
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tissues and normal tissues [2]. Therefore, CYP1B1 has 
been recognized as a potential tumor biomarker and a 
promising target for anticancer therapy [1].
Tumor-specific overexpression of CYP1B1 indicates 
its role as a regulator of tumor progression. Saini et al. 
showed that CYP1B1 knockdown inhibits endometrial 
carcinogenesis by affecting cellular proliferation, cell cycle 
and invasive potential through the regulation of cyclin E1, 
Skp2, and TRAIL [3]. In squamous cell carcinoma of the 
head and neck, CYP1B1 knockdown reduced the migration 
and proliferation of premalignant cells and CYP1B1-
mediated estrogen metabolism is essential for cancer 
development [4]. We reported that CYP1B1 expression is 
regulated by miR-200c and high CYP1B1 levels contribute 
to resistance of renal cell carcinoma (RCC) to docetaxel [5]. 
In addition, CYP1B1 reduction altered expression of CDC20 
and DAPK1 and resulted in the disturbance of cell cycle and 
apoptosis in RCC [6]. Recently, Kwon et al. suggested that 
CYP1B1-mediated Sp1 induction was critical for epithelial-
mesenchymal transition and Wnt/β-catenin signaling in 
breast cancer [7].
Caspase-1 (CASP1) was originally characterized as 
cleaving inactive pro-interleukin (IL)-1β to produce active 
IL-1β and is considered an initiator caspase [8]. In addition 
to pro-inflammatory role, CASP1 can execute programmed 
cell death [9]. Activation of CASP1 is involved in caspase-3 
activation and apoptosis induced by brain ischemia [10, 11]. 
It is required for apoptosis in Rat-1 fibroblasts as well as 
other mammalian and insect cells [8, 12]. In line with this 
evidence, CASP1 acts as a tumor suppressor regulating 
proliferation and apoptosis of epithelial cells. CASP1-
deficiency has been found to enhance tumor formation in 
mouse colorectal cancer models [13, 14]. It is also frequently 
downregulated in prostate cancer (PCa) indicating its 
loss is a potential step in malignant progression [15, 16]. 
Additionally, CASP1 activation is required for human 
PCa cells to undergo apoptosis in response to transforming 
growth factor-β [17].
PCa, the most frequently diagnosed malignancy 
among males in the United States, accounted for an 
estimated 180,890 new cases and 26,120 deaths due to 
PCa in 2016 [18]. The majority of localized and androgen-
dependent prostate cancers are generally curative by 
radical prostatectomy, radiotherapy, hormonal therapy, 
and/or neoadjuvant chemotherapy. However, no effective 
therapies are available for androgen-independent disease 
and metastatic PCa [19, 20].
CYP1B1 expression has been found in both normal 
prostate tissues and prostate tumors including normal-
adjacent tissues, with markedly higher levels in PCa 
compared with benign tissues [21, 22]. CpG methylation of 
the promoter/enhancer has been suggested as a mechanism 
controlling cancer-specific expression of CYP1B1 [22]. 
CYP1B1 metabolites such as 4-hydroxyestradiol and 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine were 
reported to induce PCa in experimental animal models 
[23, 24]. Exposure of rat prostate epithelial cells to the 
metabolites also results in DNA damage and neoplastic 
changes implicating its carcinogenic effects in the 
prostate [25]. Polymorphic variants of CYP1B1 altering 
the catabolism of estrogen may modify prostate cancer 
risk and may also predict response to chemotherapy [26]. 
These evidences strongly suggest that CYP1B1 plays a 
potentially crucial role in prostate tumor development 
and progression. However, the functional impact and 
clinicopathological significance of CYP1B1 up-regulation 
in PCa are still largely unknown.
In this study, we explored the functional role of 
CYP1B1 in the transformation and tumorigenesis of PCa. 
We also assessed the feasibility of CYP1B1 targeting for 
the treatment of PCa in an experimental animal model. 
The molecular target of CYP1B1 action and clinical 
relevance of its overexpression were also elucidated.
RESULTS
CYP1B1 overexpression stimulates 
tumorigenesis in prostate epithelial cells
CYP1B1 expression was examined in human prostate 
cell lines, which included a non-tumorigenic prostate 
epithelial cell line (RWPE-1) and prostate carcinoma cell 
lines (LNCaP, PC-3 and DU145). Relative expression of 
CYP1B1 protein (Figure 1A) and mRNA (Figure 1B) was 
amplified in all the examined cancer cell lines compared with 
the RWPE-1 cells. To explore the functional role of CYP1B1 
in PCa, we first investigated the effect of its up-regulation in 
prostate epithelial cells using RWPE-1 cell lines. Exogenous 
expression of CYP1B1 (Figure 1C) significantly enhanced 
proliferation and colony formation (Figure 1D and 1E) and 
also stimulated cell motility and invasiveness of RWPE-1 
cells (Figure 1F and 1G). In addition, DMBA, a chemical 
activator of CYP1B1 induced CYP1B1 expression in a 
dose-dependent manner (Figure 1H) and promoted growth, 
motility and invasiveness of RWPE-1 cells (Figure 1I to 1L). 
These results indicate that overexpression and activation of 
CYP1B1 regulates oncogenic activity in prostate cells.
CYP1B1 inhibition suppresses PCa 
tumorigenesis in vitro
Since CYP1B1 is up-regulated in PCa cells, we used 
a CYP1B1 knockdown approach with lentivirus-mediated 
shRNA targeting CYP1B1 to explore its biological 
significance. To this end, we generated CYP1B1 deficient 
PC-3 and DU145 cells. Among the 4 shRNA candidates, 
the CYP1B1 shRNA #4 construct in PC-3 cells and #2 
construct in DU145 cells exhibited the best efficiency 
by transient transfection and were used for establishing 
stable cell lines (Supplementary Figure 1). Subclones 
were produced from stably transfected CYP1B1 shRNAs 
and the resultant knockdown cell lines, PC-3/CYP1B1 
shRNA #4-2 and #4-3, and DU145/CYP1B1 shRNA #2-
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12 and #2-23, were selected for the further functional 
studies (Figure 2A and 2B; Supplementary Figure 2A and 
2B). No difference in cell growth and morphology was 
observed during first and the 2 days of cell growth but 
cell proliferation was significantly decreased starting 3 
days after seeding of both CYP1B1 knockdown cell lines 
(Figure 2C and Supplementary Figure 2C). Clonogenic 
assays also confirmed the impact of CYP1B1 inhibition 
on delayed growth of cells (Figure 2D and Supplementary 
Figure 2D). To further understand the growth-inhibitory 
effect of CYP1B1 reduction, we assessed apoptosis and 
cell cycle distribution by flow cytometric analysis. The 
apoptotic cell fractions were significantly increased in 
CYP1B1 knockdown cells (Figure 2E and Supplementary 
Figure 2E). However, no significant change in cell cycle 
progression was observed (Figure 2F and Supplementary 
Figure 2F). We did observe that CYP1B1 inhibition results 
in lower motility and invasiveness of PCa cells (Figure 2G 
and 2H; Supplementary Figure 2G and 2H). These results 
suggest that CYP1B1 plays a role as an oncogene in PCa 
and its targeted inhibition could suppress tumorigenesis.
CYP1B1 inhibition suppresses PCa 
tumorigenesis in vivo
To validate the antitumor effect of CYP1B1 
inhibition and further examine its use as therapeutic target 
for prostate cancer, in vivo models were utilized. In one 
Figure 1: CYP1B1 promotes cellular transformation of RWPE-1 cells. (A and B) Endogenous expression of CYP1B1 
protein (A) and mRNA (B) in PCa cells. Levels were determined by Western blot and qRT-PCR, respectively. (C–G) Effect of CYP1B1 
overexpression on in vitro tumorigenicity. Ectopic expression of CYP1B1 in transfected RWPE-1 cells as examined by Western blot (C). 
Cell proliferation as determined by MTS assay (D). Colony formation as determined by crystal violet staining. Representative image of 
colonies (left panel) and quantification of stained colonies (right panel) are shown (E). Cell migration (F) and invasion (G) capability as 
determined by transwell migration and invasion assay, respectively. (H–L) Effect of DMBA treatment on in vitro tumorigenicity. Induction 
of CYP1B1 expression in RWPE-1 cells as determined by Western blot (H). Cell proliferation as determined by MTS assay (I). Colony 
formation as determined by crystal violet staining. Representative image of colonies (left panel) and quantification of stained colonies (right 
panel) are shown (J). Cell migration (K) and invasion (L) capability as determined by transwell migration and invasion assay, respectively. 
*p<0.05; **p<0.01.
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model, CYP1B1 or control shRNA were administered 
intratumourally after allowing inoculated PC-3 cells to 
establish into tumors. As shown in Figure 3A and 3B, 
decreased growth was observed in tumors receiving 
CYP1B1 shRNA compared to those treated with control 
shRNA. The average tumor size after 5 weeks of control 
shRNA injection was 595.7±102.6 mm3 compared to 
249.3±46.6 mm3 in tumors treated with CYP1B1 shRNA. 
Administration of CYP1B1 shRNA induced low cell 
proliferation in tumors compared to those treated with 
control shRNA (Figure 3C). Reduction of CYP1B1 
protein level was confirmed in tumors injected with 
CYP1B1 shRNA (Figure 3D). In addition, PC-3 cells 
stably expressing CYP1B1 shRNA #4-2 or control shRNA 
were subcutaneously injected into the flank of nude mice. 
Decreased prostate tumor growth was observed in tumors 
Figure 2: CYP1B1 inhibition suppresses in vitro tumorigenicity. (A and B) Expression of CYP1B1 mRNA (A) and protein 
(B) in CYP1B1 shRNA or control shRNA expressing PC-3 cells. Levels were determined by qRT-PCR and Western blot, 
respectively. (C–H) Effect of CYP1B1 knockdown on in vitro tumorigenicity. Cell proliferation as determined by MTS assay 
at the indicated times. Representative images of cell morphology (left panel) and quantification of cell proliferation (right 
panel) are shown (C). Colony formation as determined by crystal violet staining. Representative image of colonies (left panel) 
and quantification of stained colonies (right panel) are shown (D). Apoptotic cell death as determined by flow cytometric 
analysis using double staining with Annexin V-FITC and 7-AAD. Representative biparametric histograms exhibiting cell (left 
panel) and quantification of apoptotic cells (right panel) are shown (E). Cell cycle progression as determined by DAPI staining 
(F). Cell migration (G) and invasion (H) capability as determined by transwell migration and invasion assay, respectively. 
Representative images (left panel) and quantification of assay (right panel) are shown. **p<0.01; ***p<0.001.
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expressing CYP1B1 shRNA #4-2 compared to those 
expressing control shRNA (Figure 3E). The average 
tumor size after 5 weeks was 792.5±116.2 mm3 in PC-3/
control shRNA cells and 240.0±81.9 mm3 in tumors stably 
expressing CYP1B1 shRNA #4-2 (Figure 3F). Tumor 
cells containing CYP1B1 shRNA displayed a significant 
difference in the number of Ki67-positive cells compared 
to cells harboring control shRNA (Figure 3G). The level 
of CYP1B1 protein was reduced in tumors expressing 
CYP1B1 shRNA (Figure 3H). These results suggest that 
CYP1B1 inhibition effectively inhibits growth of tumor 
cells in vivo and could be a therapeutic target for PCa.
Identification of a potential target of CYP1B1 
inhibition-mediated anti-tumor activity
To delineate the mechanism of the CYP1B1 
inhibition-induced antitumor effect, we looked for changes 
in gene expression in PC-3/CYP1B1 shRNA #4-2 cells 
using the Human Apoptosis RT2 Profiler PCR Array and 
Human CancerPathFinder RT2 Profiler PCR Array. From 
the genes analyzed with both arrays, we observed that the 
expression of 6 genes was significantly increased while 
the expression of 6 other genes was decreased (Table 1). 
To verify the array data, we performed qPCR assay using 
probes with a different sequence from the one used in 
the PCR arrays in both PC-3/CYP1B1 shRNA #4-2 and 
#4-3 cells. Among the genes identified from the PCR 
Array assays, changes in tumor necrosis factor receptor 
superfamily, member 9 (TNFRSF9), caspase-1 (CASP1), 
lymphotoxin alpha (LTA), CD27, spleen tyrosine kinase 
(SYK), FBJ murine osteosarcoma viral oncogene 
homolog (FOS), interleukin 8 (IL8), thrombospondin 1 
(THBS1), and V-myc myelocytomatosis viral oncogene 
homolog (MYC) were confirmed and further analyzed 
(Supplementary Figure 3A and Figure 4A). As shown by 
Western blotting, only TNFRSF9, CASP1, and THBS1 
mRNA levels were associated with changes in protein 
Figure 3: CYP1B1 inhibition suppresses in vivo tumor growth. (A to D) Effect of intratumoral injection of CYP1B1 shRNA on 
in vivo tumor growth. Volume of tumor established by PC-3 cells after administration of shRNAs for CYP1B1 or control. Representative 
image of tumors grown in mice and tumors extracted from individual mice (A) and quantification of tumor volume (B). Quantification of 
Ki67-positive cells in the control or CYP1B1 shRNA injected tumors. Representative image of section (left panel) and quantification of 
stained cells (right panel) are shown. Total 20 fields/sample were counted (C). CYP1B1 protein expression in tumors injected with control 
or CYP1B1 shRNA (D). (E–H) Effect of CYP1B1 shRNA knockdown on in vivo tumor growth using xenograft mouse model. Volume of 
tumor established by PC-3 cells stably expressing CYP1B1 shRNA #4-2 in xenografts. Representative image of tumors grown in mice and 
tumors extracted from individual mice (E) and quantification of tumor volume (F). Quantification of Ki67-positive cells in the control or 
CYP1B1 shRNA #4-2 expressing xenograft tumors. Representative image of section (left panel) and quantification of stained cells (right 
panel) are shown. Total 20 fields/sample were counted (G). CYP1B1 protein expression of control or CYP1B1 shRNA #4-2 expressing 
xenograft tumors (H). *p<0.05; **p<0.01; ***p<0.001.
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expression (Supplementary Figure 3B and 4B). TNFRSF9 
and THBS1 were the most dramatically up- and down-
regulated genes respectively among those examined and 
CASP1 also was induced 4~6-fold over controls. Among 
these, CASP1 has been shown to be significantly down-
regulated in prostate cancer [15, 16] and its genetic 
restoration reduces the tumorigenic potential by increasing 
apoptotic sensitivity [27]. Thus, we hypothesize CASP1 
to be a potential target of CYP1B1-mediated tumorigenic 
activity and antitumor effect of CYP1B1 inhibition.
CYP1B1 inhibition activates CASP1-dependent 
anti-tumorigenic activity
In addition to PC-3 cells, CYP1B1 knockdown 
induces CASP1 mRNA and protein expression in DU145 
cells (Figure 4A and 4B). Consistent with upregulation 
at the gene level, CASP1 enzyme activity was also 
significantly enhanced in both CYP1B1 knockdown 
cells (Figure 4C). To determine the impact of CASP1 
on the CYP1B1 inhibition-mediated anti-tumor effect, 
we examined the rate of cell proliferation and apoptosis. 
Treatment with Z-YVAD-fmk, a specific inhibitor of 
CASP1, accelerated the rates of proliferation in CYP1B1 
knockdown cells (Figure 4D). This may be due to the 
reduction of apoptosis by CASP1 inhibition (Figure 
4E). Next, we evaluated the effect of CASP1 in the low 
migration and invasiveness caused by CYP1B1 inhibition. 
As shown in Figure 4F and 4G, treatment with Z-YVAD-
fmk restored cell migratory and invasive characteristics of 
PCa cells, respectively. In addition to the genetic approach, 
CASP1 activity was increased by TMS, a chemical 
inhibitor of CYP1B1 (Figure 4H). Incubation with CASP1 
inhibitor deceased TMS-induced apoptosis of PC-3 cells 
(Figure 4I). On the other hand, CYP1B1 overexpression 
or activation by DMBA reduced expression and activity of 
CASP1 in RWPE-1 cells (Figure 4J and 4K). These results 
indicate that CASP1 plays a critical role in CYP1B1-
mediated tumorigenicity in PCa.
Up-regulation of CYP1B1 is associated with 
clinicopathologic characteristics of PCa patients
As shown in Figure 5A, most CYP1B1 protein was 
expressed in the glandular epithelium of PCa tissues. At 
the cellular level, it was detected in both the nucleus and 
cytoplasm. In contrast, weak or no epithelial CYP1B1 
expression was found in benign prostatic hypertrophy 
(BPH) tissues with average staining scores of 0.67±0.20 
(versus 2.17±0.22 in cancer tissues) (Figure 5B). The 
level of CYP1B1 mRNA was also significantly increased 
in PCa tissues (Figure 5C). Although high expression of 
CYP1B1 has been demonstrated in prostate tumors, there 
are no reports regarding the correlation of its expression 
with clinicopathologic characteristics. Thus, we further 
analyzed the expression pattern of CYP1B1 in clinical 
tissues to examine its relationship with clinicopathologic 
characteristics such as Gleason score, pathologic stage, 
and biochemical recurrence of PCa. Clinical demographics 
of the study cohort are summarized in Supplementary 
Table 1. Increased CYP1B1 expression (staining score ≥ 
2.0) was observed in 54.5% of patients with low Gleason 
Table 1: Summary of genes significantly altered by CYP1B1 inhibition
Symbol Fold Change Description Array
TNFRSF9 4.6 Tumor necrosis factor receptor superfamily, member 9 Apoptosis
CASP1 4.1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) Apoptosis
CD27 3.5 CD27 molecule Apoptosis
LTA 3.4 Lymphotoxin alpha (TNF superfamily, member 1) Apoptosis
BIRC8 3.0 Baculoviral IAP repeat containing 8 Apoptosis
HRK 2.9 Harakiri, BCL2 interacting protein(contains only BH3 domain) Apoptosis
SYK 0.01 Spleen tyrosine kinase Cancer PathFinder
FOS 0.08 FBJ murine osteosarcoma viral oncogene homolog Cancer PathFinder
IL8 0.11 Interleukin 8 Cancer PathFinder
THBS1 0.12 Thrombospondin 1 Cancer PathFinder
MYC 0.37 V-myc myelocytomatosis viral oncogene homolog Cancer PathFinder
NFKBIA 0.46 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Cancer PathFinder
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score (4-6), 84.0% of patients with Gleason score 7, 
and 86.7% of patients with higher Gleason score (8-10) 
(Figure 5D). This result suggests that CYP1B1 expression 
tends to increase in higher grades of PCa. No statistical 
significance was observed between CYP1B1 expression 
and pathologic stage but up-regulation of CYP1B1 
was detected in 71.0% of pT2 patients, 61.5% of pT3 
patients, and 80% of pT4 patients. Similarly, CYP1B1 
was also augmented in 11 of 13 cases (84.6%) with 
biochemical recurrence in the patient samples (Figure 5D). 
Furthermore, overall survival was significantly reduced in 
patients with high levels of CYP1B1 protein (Figure 5E).
Figure 4: CASP1 is a functional target of CYP1B1. (A–C) CASP1 mRNA (A), protein (B), and enzyme activity (C) in CYP1B1 
shRNA stably expressing PCa cells. Levels were determined by qRT-PCR, Western blot and colorimetric assay, respectively. (D–G) Effect 
of CASP1 inhibition on the tumorigenicity of CYP1B1 shRNA stably expressing PCa cells. Cells were treated with Z-YVAD-fmk (100 μM) 
and proliferation (D), apoptotic cell death (E), migration (F), as well as invasion (G) were examined, respectively. (H) Effect of chemical 
inhibition of CYP1B1 on CASP1 activation. CASP1 activity was determined by colorimetric assay in PC-3 cells treated with the indicated 
concentration of TMS. (I) Effect of CASP1 inhibition on apoptotic cell death induced by chemical inhibition of CYP1B1. Apoptotic cell 
death was determined by flow cytometric analysis using double staining with Annexin V-FITC and 7-AAD in TMS-treated PC-3 cells with 
or without addition of Z-YVAD-fmk (100 μM). (J and K) Effect of CYP1B1 activation on CASP1 in RWPE-1 cells. CASP1 expression 
was determined by Western blot after CYP1B1 overexpression (J). CASP1 activity was examined by colorimetric assay in cells treated with 
the indicated concentration of DMBA (K). *p<0.05; **p<0.01; ***p<0.001.
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CYP1B1 expression is associated with CASP1 
levels in PCa tissue
To determine whether CYP1B1 expression is 
correlated with CASP1 level, we first examined the level 
of CASP1 in prostate cancer tissue samples. As shown in 
Figure 6A and 6B, CASP1 expression was significantly 
down-regulated in human PCa. However, there was 
no statistically significant correlation between CASP1 
expression and clinicopathological characteristics (data not 
shown). Next, we categorized tissue specimens as either 
high or low CYP1B1 expression groups as previously 
determined (Figure 5D) and measured CASP1 expression. 
As shown in Figure 6C and 6D, prostate tumors with 
strong CYP1B1 expression showed low CASP1 levels. On 
the contrary, PCa samples with relatively low CYP1B1 
expression had a significantly higher level of CASP1 
expression as compared to those with high CYP1B1 
expression. In addition, increased CASP1 expression was 
found in the tumors injected with or stably expressing 
CYP1B1 shRNA (Figure 6E and 6F).
DISCUSSION
Since CYP1B1 is implicated as an important factor 
in the development of various cancers, understanding 
the precise mechanisms of CYP1B1-mediated cancer 
progression is required in the development of new 
strategies for cancer treatment. CYP1B1 provokes an 
oncogenic phenotype by damaging DNA through the 
formation of 8-hydroxy-2’-deoxyguanosine [28]. Recently, 
several molecular targets of CYP1B1 have been found and 
indicate the participation of CYP1B1 in multiple pathways 
during the progression of various types of cancer [3, 4, 6, 
7]. In line with these efforts, our study found that CASP1 
Figure 5: Association of CYP1B1 expression with clinicopathologic characteristics of PCa. (A–C) CYP1B1 expression 
in PCa tissues. Immunohistochemical staining of CYP1B1 protein in PCa specimens. Representative images showing immunoreactive 
CYP1B1 in BPH and cancer tissues (magnification: ×200) (A). Summary of CYP1B1 immunostaining score. Staining intensity was 
assessed as described in Materials and Methods (B). CYP1B1 mRNA expression in microdissected prostate tissues (C). (D) Correlation 
of CYP1B1 expression with clinicopathological characteristics of patients with PCa. †Data was not available for some samples. *p<0.05; 
***p<0.001 (E) Kaplan-Meier survival curves for overall survival of patients with PCa. p=0.0111.
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is a critical mediator of CYP1B1-induced tumorigenicity 
in PCa.
CASP1 is an apical activator of the cell death 
pathway [9] and its overexpression has been shown 
to induce apoptosis in mammalian cells [12, 29]. 
Exogenous expression of CASP1 markedly reduced the 
growth of renal cancer cells in vitro and in vivo, and 
silencing CASP1 activity resulted in the establishment 
of solid tumors [30]. Down-regulation of CASP1 was 
found in human colon cancer [31] and enhanced tumor 
formation in a colitis-associated colorectal cancer model 
[13]. Furthermore, CASP1 is frequently downregulated 
in prostate cancer [15, 16] and its genetic restoration 
reduces the tumorigenic potential via apoptosis [27, 32]. 
2,3,7,8-Tetrachlorodibenzo-p-dioxin, a strong CYP1B1 
activator, suppressed activities of CASP1 and CASP3 
in the apoptotic cell death of hepatocytes [33]. In this 
study, we found that CASP1 is significantly up-regulated 
Figure 6: Inverse correlation between CYP1B1 and CASP1 expression. (A and B) Immunohistochemical staining of CASP1 
protein in PCa specimens. Representative images showing immunoreactive caspase-1 in BPH and cancer tissues (magnification: × 200) 
(A). Summary of CASP1 immunostaining score (B). (C and D) Immunohistochemical staining of CYP1B1 and CASP1 protein in prostate 
cancer specimens. Representative images showing inverse correlation of CYP1B1 and CASP1 in BPH and cancer tissues (magnification: × 
200) (C). Summary of CASP1 immunostaining score (D). (E and F) Expression of CASP1 mRNA in tumors injected with CYP1B1 shRNA 
(E) and PC-3/CYP1B1 shRNA #4-2 xenografts (F). *p<0.05.
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by CYP1B1 inhibition and is a newly identified target 
molecule of CYP1B1-mediated tumorigenesis. CASP1 is 
silenced by DNA methylation in renal cancer [30]. Given 
that CYP1B1 knockdown increases CASP1 (Figure 4), we 
suggest an alternative mechanism for CASP1 suppression 
and its critical role in CYP1B1-mediated regulation of 
PCa progression.
According to Gregoraszczuk et al., 17β-estradiol 
(E2) increases CYP1B1 protein expression, changing the 
local metabolic activation pathway to increased 4-OHE2 
production. Both E2 and 4-OHE2 decrease CASP9 activity 
[34]. Therefore, it is possible that reduction of 4-OHE2 
levels by CYP1B1 suppression may lead to CASP1 
activation. CYP enzyme promotes reactive oxygen species 
(ROS) generation which occurs during the metabolic 
conversion of procarcinogens to their ultimate reactive 
electrophilic intermediates [35]. However, interestingly, 
a lack of CYP1B1 expression and/or activity leads to 
accumulation of ROS and increased intracellular oxidative 
stress in retinal endothelial cells, perivascular supporting 
cells, and trabecular meshwork cells [36–38]. Moreover, 
CASP1 can be activated by ROS [39, 40]. Therefore, it 
is plausible that ROS produced by CYP1B1 inhibition 
activates CASP1 which induces antitumor effects in 
PCa cells. Due to a contradictory report suggesting that 
CYP1B1 shRNA reduces ROS production in vascular 
smooth muscle cell [41], this hypothesis needs further 
clarification. In contrast to previous findings [27, 30–
32], CASP1 has an anti-apoptotic effect in pancreatic 
carcinoma [42]. Thus, it would be of interest to examine 
the expression and function of CYP1B1 in pancreatic 
cancer and determine its relationship with CASP1.
To analyze the therapeutic potential of lentivirus-
delivered CYP1B1 shRNA, we performed a pre-clinical 
study. The recombinant lentivirus expressing CYP1B1 
shRNA was intratumorally injected into established tumors 
or tumor cells expressing CYP1B1 shRNA were injected 
into nude mice. Both approaches suppressed the growth of 
tumors arising from PC-3 cells. These results demonstrate 
that CYP1B1 inhibition by lentivirus-mediated shRNA 
resulted in a beneficial effect in vivo. To our knowledge, 
our study is the first report determining the therapeutic 
effect of lentivirus expressing CYP1B1 shRNA. Shariat et 
al. showed that an adenoviral vector expressing inducible 
form of CASP1 can inhibit the growth of PCa in vitro and 
in vivo by the induction of apoptosis [32]. In contrast to 
adenoviruses, a lentivirus-based strategy does not trigger 
a potentially dangerous immune response. Therefore, it 
is ideally suited for use in human cancer cells. Further 
development of a lentiviral vector expressing CYP1B1 
shRNA may result in a protective effect in vivo against 
PCa.
CYP1B1 is overexpressed in a variety of human 
tumor cells including prostate cancer [2, 22, 43, 44]. 
However, its association with clinicopathological features 
has not been elucidated. Here, we demonstrate that high 
levels of CYP1B1 are associated with parameters such 
as Gleason score and survival rate of PCa patients. Thus, 
CYP1B1 could be a potential prognostic and diagnostic 
marker for PCa. We also found that CYP1B1 expression 
is inversely associated with CASP1 levels in human 
PCa tissues (Figure 6). Consistent with a previous study 
[15], we could find no statistically significant correlation 
between CASP1 expression and clinicopathological 
parameters including Gleason score of PCa tissues 
probably due to the relatively small number of tissue 
samples. Analysis of a larger group of tumors with more 
cases in the different histological grade categories will 
be required to determine an association between CASP1 
expression and clinical parameters of PCa. In addition, it 
will be of interest to perform studies on the association 
of CYP1B1 expression and its polymorphic variants with 
CASP1 expression in PCa patients.
In summary, the present study demonstrates 
that CYP1B1 induces tumorigenecity of PCa cells by 
modulating CASP1 expression. We also presented data 
indicating the feasibility of using in vivo lentivirus-
delivered CYP1B1 shRNA to reduce the tumor burden in 
animals. This result supports the idea that attenuation of 
CYP1B1 may be useful in the treatment of PCa. Finally, 
we show the clinical relevance and inverse correlation 
between CYP1B1 and CASP1 in human tissue specimens. 
Thus, we believe the findings of this study may provide 
a new mechanistic interpretation for CYP1B1-induced 
development and progression of PCa.
MATERIALS AND METHODS
Cell lines and reagents
Human PCa cell lines (LNCaP, PC-3, and DU145) 
and a non-malignant epithelial prostate cell line (RWPE-
1) were purchased from the ATCC (Manassas, VA). 
Keratinocyte serum-free medium (K-SFM), bovine 
pituitary extract and human recombinant epidermal 
growth factor were purchased from Invitrogen (Carlsbad, 
CA). RPMI 1640, EMEM, Opti-MEM and penicillin/
streptomycin mixtures were obtained from the UCSF 
Cell Culture Facility (San Francisco, CA). Fetal bovine 
serum (FBS) was a product of Atlanta Biologicals 
(Lawrenceville, GA). Z-YVAD-fmk was purchased from 
Santa Cruz Biotechnology (Santa Cruz). N-acetylcysteine 
(NAC), 7,12-Dimethylbenz[a]anthracene (DMBA), and 
2,3’,4,5’-Tetramethoxystilbene (TMS) were obtained from 
Sigma (St. Louis, MO).
Cell culture
LNCaP and PC-3 cells were grown in RPMI 1640 
and DU145 cells were cultured in EMEM. All culture 
medium contained 10% FBS and 100 μg/ml penicillin/
streptomycin. RWPE-1 cells were cultured in K-SFM 
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supplemented with 0.05 mg/ml bovine pituitary extract 
and 5 ng/ml human recombinant epidermal growth factor. 
All cell lines were maintained at 37°C in a humidified 
atmosphere composed of 5% CO2 and 95% air.
Western blot analysis
Whole cell extracts from cultured cells were 
prepared using radioimmunoprecipitation assay buffer 
(Thermo Scientific, Waltham, MA) containing protease 
inhibitor cocktail (Roche Diagnostics, Risch-Rotkreuz, 
Swizerland). Immunoblotting was carried out according 
to standard protocols with antibodies against TNFRSF9 
(Sigma), LTA (GeneTex, San Antonio, TX), CYP1B1, 
CD27, IL8, THBS1 (Abcam, Cambridge, MA), SYK, 
FOS, MYC, NFKBIA, CASPASE-1 (Cell Signaling 
Technology, Danvers, MA). Antibody against GAPDH 
(Santa Cruz Biotechnology, Santa Cruz, CA) and β-actin 
(Abcam) was used to confirm equal loading.
Establishment of stably expressing plasmid or 
short hairpin (sh) RNA specific for CYP1B1
Ectopic expression of CYP1B1 plasmid (OriGene 
Techologies, Rockville, MD) in RWPE-1 cells and 
CYP1B1 shRNA (Origene) in PC-3 and DU145 cells 
along with their controls were achieved using lentivirus as 
per the manufacturer’s instructions. The transduced cells 
were then selected using puromycin (1 μg/ml; Sigma).
Cell proliferation and colony formation assay
For 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-
based cell proliferation assays, cells were plated in 
triplicate in 96-well plates at a density of 5×103 cells per 
well. At the desired time point, the number of viable cells 
was determined by adding CellTiter 96 AQueous One 
Solution reagent (Promega, Madison, WI) to each well 
and measuring the absorbance at 490 nm on a SpectraMax 
190 plate reader (Molecular Devices, Sunnyvale, CA). 
Results were expressed as percent optical density with 
absorbance of control cells being 100%. To assess colony 
formation, cells were plated in triplicate in 6-well plates at 
a density of 1×102 cells per well. At the desired time point, 
colonies were identified by adding 1% paraformaldehyde 
followed by incubating in 0.1% crystal violet. The number 
of colonies was quantified by dissolving them in methanol 
and measuring the absorbance at 540 nm on a SpectraMax 
190 plate reader.
Apoptosis and cell cycle assay
For apoptosis assays, cells were stained with an 
Annexin V-fluorescein isothiocyanate (FITC)/7-amino-
actinomycin D (7-AAD) (BD Biosciences, San Diego, 
CA) as described by the manufacturer. Both early and late 
apoptotic cells were included in cell death determinations. 
For cell cycle analysis, cells were stained with 4’, 
6-diamidino-2-phenylindole (DAPI). Both assays were 
analyzed by a Cell Lab Quanta™ SC MPL (Beckman 
Coulter, Fullerton, CA).
Migration and invasion assay
Cell migration and invasion were measured using 
the CytoSelectTM 24-Well Cell Migration and Invasion 
Assay (Cell Biolabs, San Diego, CA). Stained invasive and 
migratory cells were observed with a Nikon microscope 
and quantified using a SpectraMax plate reader at 560 nm.
In vivo intratumoral delivery and xenograft 
mouse model
All animal care was in accordance with current 
guidelines and this study was approved by the San 
Francisco Veterans Affairs IACUC (Institutional Animal 
Care and Use Committee). For intratumoral injection 
of lentivirus-mediated CYP1B1 shRNA, five week old 
male mice (Charles River, Burlington, MA) were injected 
subcutaneously into the dorsal flank area with 200 μl of 
RPMI 1640 medium containing PC-3 cells (5×106 cells). 
Once tumors reached a volume of 30-40 mm3, the tumors 
were injected every 3 days with 50 μl (4×107 cells) of viral 
particles containing CYP1B1 or control shRNA. For the 
subcutaneous xenograft mouse model, PC-3 cells (5×106 
cells) stably transfected with either CYP1B1 shRNA 
#4-2 or control shRNA suspended in 100 μl RPMI 1640 
medium were subcutaneously injected into the right 
backside flank of five week old male nude mice. Six to 
eight nude mice were used per treatment group and tumor 
growth was examined over the course of 35 days. Tumor 
volume was calculated on the basis of width (x) and length 
(y) using the formula: x2y/2, where x<y.
Immunohistochemistry
Written informed consent for the use of the tissues 
was obtained from all patients before surgery, and the 
study was approved by the Clinical Research Office 
of the San Francisco Veterans Affairs Medical Center 
and the Institutional Review Board of the University 
of California at San Francisco. Immunostaining was 
performed on formalin-fixed paraffin embedded PCa 
sections using the VECTASTAIN ABC Kit (Vector 
Laboratories, Burlingame, CA) according to the 
manufacturer’s instructions. After incubation with anti-
CYP1B1 and CASP1 antibodies (Abcam), ImmPACT 
DAB (Vector Laboratories) was added as chromogen 
followed by counterstaining with hematoxylin. Staining 
intensity of each tissue section was visually evaluated 
with an Olympus BX60 microscope equipped with Spot 
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Advanced software (Diagnostic Instruments, Sterling 
Heights, MI) and was ranked on an overall scale from 0 
to 3; with 0 indicating the absence of staining; 1, weak 
staining; 2, moderate staining; and 3, strong staining. For 
Ki67 staining, tumor sections were stained with Anti-Ki67 
antibody (Abcam) and positive cells were counted from 
at least 3 randomly selected microscopic fields with % 
positivity calculated.
Quantitative RT-PCR
Total RNA was isolated using the RNeasy Mini 
Kit (Qiagen, Valencia, CA, USA) and was converted 
into cDNA by using the iScript™ cDNA Synthesis Kit 
(Bio-Rad, Hercules, CA) according to the manufacturer’s 
instructions. To assess gene expression, cDNAs were 
amplified with the TaqMan® Gene Expression Assays 
and TaqMan Fast Universal PCR Master Mix using the 
7500 Fast Real-Time PCR System (Applied Biosystems, 
Foster City, CA). To investigate the expression of 
genes regulated by CYP1B1 inhibition, the RT2 
Profiler PCR Array Human Apoptosis and Human 
Cancer PathwayFinder (SABiosciences, Frederick, 
MD) were used as per manufacturer’s instructions. Each 
array contains quantitative PCR primers of 84 known 
apoptosis- or tumorigenesis-related genes, respectively. 
The relative change in gene expression was calculated 
by the comparative Ct (threshold cycle) method using the 
7500 Fast System Sequence Detection Software (Applied 
Biosystems).
Caspase-1 enzymatic activity assay
Caspase-1 activation was measured using a 
Caspase-1/ICE Colorimetric Assay Kit as described by the 
supplier’s instructions (R&D Systems, Minneapolis, MN).
Statistical analysis
Values in Figures are presented as the 
mean±standard error of mean (SEM) based on results 
obtained from at least three independent experiments. For 
in vivo studies, results are based on six animals per group. 
All statistical analyses were carried out using GraphPad 
PRISM Software. Two-tailed unpaired Student’s t-test 
was used for comparisons between two groups. Chi-
square test was used for analyzing the correlation between 
clinicopathologic parameters and CYP1B1 protein 
expression. Significance of percent survival was done 
with log-rank test. A P value of <0.05 was regarded as 
statistically significant.
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